Clinical Trials Logo

Stage IV Non-small Cell Lung Cancer clinical trials

View clinical trials related to Stage IV Non-small Cell Lung Cancer.

Filter by:

NCT ID: NCT03911219 Not yet recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Study to Evaluate the Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC or SCLC Under 1st-line Treatment With Atezolizumab and Platinum-based Chemotherapy

CHAPLIN
Start date: April 2019
Phase:
Study type: Observational

The current study is aimed to test the benefit of a web-based application tool in NSCLC and SCLC patients during the recently approved first-line treatment strategy with atezolizumab in combination with platinum-based chemotherapy.

NCT ID: NCT03838848 Not yet recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

KN046 in Patients With Advanced Non-small Cell Lung Cancer

Start date: March 2019
Phase: Phase 2
Study type: Interventional

This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.

NCT ID: NCT03742687 Recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC

Start date: November 22, 2018
Phase: N/A
Study type: Interventional

The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive dose to the healthy tissue in the thorax, or with performance status not supporting seven weeks of intensive treatment. The aim is to study the efficiency as well as the safety of a new treatment option of heterogeneously hypofractionated radiotherapy for patients with locally advanced NSCLC who are not candidates for standard, high-dose chemoradiotherapy, either due to excessive irradiation of normal tissue (defined as category A patients) or due to fragility of the patient (category B patients).

NCT ID: NCT03611738 Recruiting - Lung Cancer Clinical Trials

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Start date: October 31, 2018
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to find out what effects (good and bad) ceritinib (Zykadia®) used in combination with docetaxel (Taxotere®) will have on participants and their cancer. The results will help to determine the best safe dose of the combination of the medications Ceritinib (Zykadia®) and docetaxel (Taxotere®) and to find out if this combination of drugs will help people that have this type of Non-small Cell Lung Cancer (NSCLC).

NCT ID: NCT03595644 Recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer

Start date: July 12, 2018
Phase: Phase 2
Study type: Interventional

This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with a targeted agent such as gefitinib, erlotinib and icotinib.

NCT ID: NCT03559049 Recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Start date: December 24, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multi-center, Phase I/II, single arm trial to assess the safety and efficacy of the combination of oral rucaparib plus intravenous pembrolizumab as maintenance therapy in patients with stage IV non-squamous non-small cell lung cancer (NSCLC) without progressive disease (PD), as confirmed on CT scans, after induction therapy with carboplatin/pemetrexed/pembrolizumab (CPP) triplet therapy.

NCT ID: NCT03305380 Recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth

Start date: September 1, 2017
Phase:
Study type: Observational [Patient Registry]

The investigators will develop a radiomics signature for immune checkpoint-induced pneumonitis in 40 patients with a pulmonary event under anti-PD1 or anti-PD-L1 (cases) and 40 patients without a pulmonary event under anti-PD1 or anti-PD-L1 (controls). On the basis of the case-control study of patients treated with anti-PD1 or anti-PD-L1, they will further optimise the model using reinforcement machine learning. The model will then be validated in 300 prospective patients.

NCT ID: NCT03199651 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

BLCIO
Start date: July 17, 2017
Phase: N/A
Study type: Interventional

This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorable toxicity profiles than conventional chemotherapy and impact quality of life.

NCT ID: NCT03176173 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy

Start date: June 28, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radical-dose image guided radiation therapy to patients with non-small cell lung cancer may help to improve response to immunotherapy anti-cancer treatment.

NCT ID: NCT03154190 Recruiting - Clinical trials for Acute Myeloid Leukemia

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Start date: December 15, 2016
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer. Health care coach support may help cancer patients to make decisions about their care that matches what is important to them with symptom management.